Ticker
AKRO

Price
13.18
Stock movement up
+1.13 (9.38%)
Company name
Akero Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
494.89M
Ent value
367.75M
Price/Sales
-
Price/Book
3.38
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-39.95%
3 year return
-22.36%
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AKRO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book3.38
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count37.55M
EPS (TTM)-3.20
FCF per share (TTM)-2.41

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)-85.76M
Operating income (TTM)-111.81M
Net income (TTM)-111.72M
EPS (TTM)-3.20
EPS (1y forward)-3.55

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash150.49M
Net receivables0.00
Total current assets167.93M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets169.89M
Accounts payable4.45M
Short/Current long term debt1.47M
Total current liabilities22.10M
Total liabilities23.35M
Shareholder's equity146.53M
Net tangible assets146.53M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-84.21M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-84.21M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-76.24%
Return on Assets-65.76%
Return on Invested Capital-76.24%
Cash Return on Invested Capital-57.47%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open12.08
Daily high13.34
Daily low11.90
Daily Volume518K
All-time high39.92
1y analyst estimate37.17
Beta0.62
EPS (TTM)-3.20
Dividend per share-
Ex-div date-
Next earnings date10 Nov 2022

Downside potential

Loading...
Downside potential data
AKROS&P500
Current price drop from All-time high-66.98%-13.41%
Highest price drop-79.96%-56.47%
Date of highest drop1 Jun 20229 Mar 2009
Avg drop from high-35.39%-11.38%
Avg time to new high47 days12 days
Max time to new high537 days1805 days
COMPANY DETAILS
AKRO (Akero Therapeutics Inc) company logo
Marketcap
494.89M
Marketcap category
Small-cap
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Employees
35
Investor relations
-
SEC filings
CEO
Andrew Cheng
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Coliseum Capital acquired almost half of the publicly traded shares of mattress firm Purple. OrbiMed Advisors increased its stake in pharmaceutical firm Edgewise Therapeutics.
September 23, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...
September 19, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...
September 15, 2022
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
September 14, 2022
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. When looking for the best stocks to buy and watch, one factor to watch clos...
September 14, 2022
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
September 14, 2022
POINT Biopharma Global Inc (NASDAQ: PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds of $125 million. The offer price represents a discount of almost 12% ...
September 14, 2022
Akero wowed investors Tuesday with midstage test results for a hepatitis treatment, and the biotech stock skyrocketed by triple digits.
September 13, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...
September 13, 2022
With more than 17 million Americans with NASH, the fatty liver disease has been a prime target for drug developers. But few have been able to show promising clinical trial results.
September 13, 2022
Next page